From PR Newswire: Allievex Corporation ("Allievex"), a clinical-stage biotechnology company founded by Pappas Capital, today announced the completion of a Series A financing co-led by Novo Holdings and Pappas Capital. Allievex has also appointed Kyle Rasbach, Ph.D., PharmD., Managing Partner at Pappas Ventures and Tiba Aynechi, Ph.D., Partner at Novo Holdings, to its Board of Directors. Read the full press release here.
top of page
Related PostsSee All
A mother is desperately seeking access to a trial drug for her nine-year-old son that she hopes could save his life. Severine Hamilton is trying to obtain a prototype enzyme replacement therapy for he
From Boston Herald: My small biopharma company is developing a drug to treat a rare, fatal and presently incurable disease that afflicts one in 70,000 children. We are working around-the-clock to tes
From Sanfilippo News: Allievex, a new clinical-stage biotechnology company founded by Pappas Capital, will continue the clinical program of BioMarin Pharmaceutical‘s tralesinidase alfa (formerly know
bottom of page